CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TAF13 (ImmuneEditome ID:6884)

1. Gene summary of enriched editing regions for TAF13

check button Gene summary
Gene informationGene symbol

TAF13

Gene ID

6884

GeneSynonymsMRT60|TAF(II)18|TAF2K|TAFII-18|TAFII18
GeneCytomap

1p13.3

GeneTypeprotein-coding
GeneDescriptiontranscription initiation factor TFIID subunit 13|TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 18kDa|TATA box binding protein (TBP)-associated factor, RNA polymerase II, K, 18kD|transcription initiation factor TFIID 18 kD subunit|transcription initiation factor TFIID 18 kDa subunit
GeneModificationdate20230329
UniprotIDQ15543;A0A8J9AJQ9;A0A024R089;A0A8I5KR19
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:109063122-109064145:-ENST00000338366.5ENSG00000197780.8TAF13UTR3AluY,AluSz6,AluScchr1:109063122-109064145:-.alignment


Top

2. Tumor-specific enriched editing regions for TAF13


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:109063122-109064145:-BRCAEER8.2000e-04image
ENSG00000197780.8,TAF13BRCAEAG4.8385e-04image
chr1:109063122-109064145:-LUADEER4.7800e-04image
ENSG00000197780.8,TAF13LUADEAG5.2985e-04image
chr1:109063122-109064145:-LUSCEER4.0341e-02image
ENSG00000197780.8,TAF13LUSCEAG4.1859e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000197780.8,TAF13BRCAPathEAG2.7217e-021.3514e-020.0763image
chr1:109063122-109064145:-KIRPCliEER1.2388e-023.2693e-020.1674image
ENSG00000197780.8,TAF13KIRPCliEAG1.0388e-024.3300e-020.1585image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr1:109063122-109064145:-ESCAEER4.3521e-021.5964e-031.7310e+04image
chr1:109063122-109064145:-UCECEER4.7646e-022.5830e-022.2134e+02image
ENSG00000197780.8,TAF13UCECEAG3.8906e-021.9241e-022.5854e+02image

Top

3. Enriched editing regions and immune related genes for TAF13


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:109063122-109064145:-DLBCEERENSG00000140563,MCTP2-0.70821.0271e-021.0905e-03-0.5156imageNNNAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr1:109063122-109064145:-DLBCEERENSG00000136603,SKIL-0.72241.0508e-022.0952e-03-0.4897imageNNSKILMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr1:109063122-109064145:-DLBCEERENSG00000156931,VPS8-0.71471.1723e-022.8094e-03-0.4774imageNNNAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr1:109063122-109064145:-DLBCEERENSG00000217716,RPS10P30.71941.2531e-021.0327e-030.5177imageNNNAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr1:109063122-109064145:-DLBCEERENSG00000133740,E2F5-0.68811.2935e-024.7912e-03-0.4538imageNNNAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:109063122-109064145:-DLBCEERENSG00000171109,MFN1-0.68621.4592e-021.5987e-03-0.5007imageNNMFN1B_cells_naiveGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr1:109063122-109064145:-DLBCEERENSG00000170396,ZNF804A-0.68861.9081e-021.2213e-02-0.4079imageNNNAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr1:109063122-109064145:-DLBCEERENSG00000196189,SEMA4A-0.67152.1682e-021.0258e-02-0.4169imageNNSEMA4A
chr1:109063122-109064145:-DLBCEERENSG00000182923,CEP63-0.67382.2414e-026.1745e-04-0.5366imageNNNAB_cells_naiveGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr1:109063122-109064145:-DLBCEERENSG00000100916,BRMS1L-0.65562.3553e-021.3949e-03-0.5061imageNNNAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for TAF13


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000197780.8,TAF13
COADEAGIRENSG00000013374.11chr7151368734:151374243:151375847:1513759430.28196.8393e-032.8589e-170.5408imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NUB1EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197780.8,TAF13
COADEAGIRENSG00000164402.9chr5132756004:132758824:132760801:1327608710.25573.4188e-025.0853e-120.4436imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZC3H7B;ZNF184NAMast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197780.8,TAF13
COADEAGIRENSG00000180573.8chr626124144:26127761:26138053:261390840.22814.8240e-021.8239e-170.5608imageNACIN1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZC3H7B;ZNF184NANeutrophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000197780.8,TAF13
COADEAGIRENSG00000144591.13chr2219504082:219504213:219505227:2195052590.24664.1734e-021.7592e-190.5590imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000197780.8,TAF13
COADEAGIRENSG00000090006.13chr1940622904:40623021:40623603:406236330.27921.1139e-021.2243e-160.5210imageNACIN1;ADAR;ALYREF;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184LTBP4EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197780.8,TAF13
COADEAGIRENSG00000154122.8chr514704803:14711310:14712873:147129730.26062.7547e-021.2866e-100.4160imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RBM5;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000197780.8,TAF13
COADEAGIRENSG00000060971.13chr338122709:38123122:38125564:381257100.26342.1981e-026.4228e-150.4937imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197780.8,TAF13
COADEAGMEXENSG00000137648.12chr11118104690:118104820:118107773:118107875:118111814:118111900:118113268:118113435-0.25553.4791e-022.3222e-13-0.4678imageNADAR;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHDRBS1;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PRPF8;PTBP1;RBM22;SAFB2;SMNDC1;SND1;SRSF1;TAF15;TARDBP;U2AF1;U2AF2;UPF1;XRN2NADendritic_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
ENSG00000197780.8,TAF13
COADEAGIRENSG00000104936.13chr1945779777:45779869:45782192:457823880.22574.9250e-029.7279e-100.4282imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZC3H7B;ZNF184NAMast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000197780.8,TAF13
COADEAGIRENSG00000085998.9chr146190472:46190517:46190719:461907840.24234.9321e-024.4316e-310.6812imageNADAR;ALYREF;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

5. Enriched editing regions and immune infiltration for TAF13


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:109063122-109064145:-ACCEERT_cells_regulatory_(Tregs)3.6352e-020.2731image
ENSG00000197780.8,TAF13ACCEAGT_cells_regulatory_(Tregs)3.6352e-020.2731image
chr1:109063122-109064145:-BLCAEERT_cells_CD81.0895e-040.2034image
ENSG00000197780.8,TAF13BLCAEAGT_cells_CD81.0986e-040.2033image
chr1:109063122-109064145:-BRCAEERMacrophages_M15.0955e-050.1247image
ENSG00000197780.8,TAF13BRCAEAGMacrophages_M16.5276e-050.1228image
chr1:109063122-109064145:-CESCEERT_cells_regulatory_(Tregs)1.2201e-020.1473image
ENSG00000197780.8,TAF13CESCEAGT_cells_regulatory_(Tregs)1.2201e-020.1473image
chr1:109063122-109064145:-CHOLEERT_cells_CD4_naive2.7329e-030.4912image
ENSG00000197780.8,TAF13CHOLEAGT_cells_CD4_naive2.7329e-030.4912image
chr1:109063122-109064145:-COADEERNK_cells_activated4.2085e-020.1378image
ENSG00000197780.8,TAF13COADEAGEosinophils4.4129e-030.1913image
chr1:109063122-109064145:-GBMEERMacrophages_M01.4995e-03-0.2460image
ENSG00000197780.8,TAF13GBMEAGMacrophages_M01.5174e-03-0.2457image
chr1:109063122-109064145:-HNSCEERMacrophages_M11.5209e-040.1708image
ENSG00000197780.8,TAF13HNSCEAGMacrophages_M11.5209e-040.1708image
chr1:109063122-109064145:-KIRCEERT_cells_CD83.1750e-030.1557image
ENSG00000197780.8,TAF13KIRCEAGT_cells_CD83.1595e-030.1558image
chr1:109063122-109064145:-KIRPEERT_cells_gamma_delta1.5656e-020.1575image
ENSG00000197780.8,TAF13KIRPEAGT_cells_gamma_delta2.9134e-020.1424image
ENSG00000197780.8,TAF13LAMLEAGT_cells_CD4_memory_resting1.4254e-020.5263image
chr1:109063122-109064145:-LGGEERT_cells_follicular_helper1.0987e-02-0.1129image
ENSG00000197780.8,TAF13LGGEAGT_cells_follicular_helper1.1024e-02-0.1128image
chr1:109063122-109064145:-LIHCEERNK_cells_activated1.4062e-030.1730image
ENSG00000197780.8,TAF13LIHCEAGNK_cells_activated1.4348e-030.1727image
chr1:109063122-109064145:-LUADEERT_cells_CD4_memory_activated8.5025e-040.1498image
ENSG00000197780.8,TAF13LUADEAGT_cells_CD89.5361e-040.1482image
chr1:109063122-109064145:-LUSCEERT_cells_CD82.0011e-050.1935image
ENSG00000197780.8,TAF13LUSCEAGT_cells_CD81.8538e-050.1943image
chr1:109063122-109064145:-MESOEERT_cells_CD81.3911e-020.2757image
ENSG00000197780.8,TAF13MESOEAGT_cells_CD81.3911e-020.2757image
chr1:109063122-109064145:-OVEERT_cells_follicular_helper7.9690e-050.2315image
ENSG00000197780.8,TAF13OVEAGT_cells_follicular_helper7.6226e-050.2321image
chr1:109063122-109064145:-PAADEERNK_cells_resting5.0293e-030.2142image
ENSG00000197780.8,TAF13PAADEAGNK_cells_resting5.0293e-030.2142image
chr1:109063122-109064145:-PCPGEERT_cells_gamma_delta4.9967e-020.1626image
ENSG00000197780.8,TAF13PCPGEAGT_cells_gamma_delta4.9840e-020.1626image
chr1:109063122-109064145:-SARCEERMacrophages_M23.2795e-020.1402image
ENSG00000197780.8,TAF13SARCEAGMacrophages_M23.5410e-020.1382image
chr1:109063122-109064145:-SKCMEERT_cells_CD85.0371e-040.1657image
ENSG00000197780.8,TAF13SKCMEAGT_cells_CD85.0739e-040.1656image
chr1:109063122-109064145:-STADEERNK_cells_activated9.2131e-050.2108image
ENSG00000197780.8,TAF13STADEAGNK_cells_activated3.2510e-050.2236image
chr1:109063122-109064145:-TGCTEERMacrophages_M22.4573e-04-0.2981image
ENSG00000197780.8,TAF13TGCTEAGMacrophages_M22.4573e-04-0.2981image
chr1:109063122-109064145:-THCAEERT_cells_regulatory_(Tregs)2.7255e-020.1027image
ENSG00000197780.8,TAF13THCAEAGT_cells_regulatory_(Tregs)2.6949e-020.1029image
chr1:109063122-109064145:-THYMEERT_cells_CD4_naive2.4337e-03-0.3091image
ENSG00000197780.8,TAF13THYMEAGT_cells_CD4_naive2.4337e-03-0.3091image
chr1:109063122-109064145:-UCECEERDendritic_cells_activated1.7302e-030.2489image
ENSG00000197780.8,TAF13UCECEAGDendritic_cells_activated7.7746e-040.2655image
chr1:109063122-109064145:-UCSEERMast_cells_resting1.0277e-020.3403image
ENSG00000197780.8,TAF13UCSEAGMast_cells_resting1.0277e-020.3403image
chr1:109063122-109064145:-UVMEERB_cells_naive3.1651e-020.3692image
ENSG00000197780.8,TAF13UVMEAGB_cells_naive3.1651e-020.3692image


Top

6. Enriched editing regions and immune gene sets for TAF13


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000197780.8,TAF13BLCAEAG1.5961e-030.16652.8839e-020.11577.5614e-030.14124.6854e-020.1053image
chr1:109063122-109064145:-BLCAEER1.5771e-030.16672.9009e-020.11567.4949e-030.14134.6307e-020.1055image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:109063122-109064145:-ACCGSVA_HALLMARK_MYOGENESISEER4.5800e-03-0.3641image
ENSG00000197780.8,TAF13ACCGSVA_HALLMARK_MYOGENESISEAG4.5800e-03-0.3641image
chr1:109063122-109064145:-BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.6679e-060.2376image
ENSG00000197780.8,TAF13BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.8519e-060.2372image
ENSG00000197780.8,TAF13BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.0495e-200.2802image
chr1:109063122-109064145:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.4412e-200.2763image
chr1:109063122-109064145:-CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0642e-05-0.2558image
ENSG00000197780.8,TAF13CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0642e-05-0.2558image
ENSG00000197780.8,TAF13CHOLGSVA_HALLMARK_P53_PATHWAYEAG3.6512e-03-0.4784image
chr1:109063122-109064145:-CHOLGSVA_HALLMARK_P53_PATHWAYEER3.6512e-03-0.4784image
chr1:109063122-109064145:-COADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER5.8954e-03-0.1859image
ENSG00000197780.8,TAF13COADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG9.8138e-06-0.2932image
chr1:109063122-109064145:-DLBCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.7825e-03-0.4538image
ENSG00000197780.8,TAF13DLBCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.7825e-03-0.4538image
chr1:109063122-109064145:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6960e-040.2759image
ENSG00000197780.8,TAF13ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9673e-040.2920image
ENSG00000197780.8,TAF13GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.2377e-050.3185image
chr1:109063122-109064145:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.8266e-050.3207image
ENSG00000197780.8,TAF13HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.9837e-100.2770image
chr1:109063122-109064145:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.9837e-100.2770image
chr1:109063122-109064145:-KICHGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.1638e-02-0.3578image
ENSG00000197780.8,TAF13KICHGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.1638e-02-0.3578image
chr1:109063122-109064145:-KIRCGSVA_HALLMARK_HEME_METABOLISMEER2.4596e-03-0.1598image
ENSG00000197780.8,TAF13KIRCGSVA_HALLMARK_HYPOXIAEAG2.4541e-03-0.1598image
ENSG00000197780.8,TAF13KIRPGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.0490e-04-0.2503image
chr1:109063122-109064145:-KIRPGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.4380e-04-0.2455image
ENSG00000197780.8,TAF13LAMLGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.7639e-03-0.6404image
ENSG00000197780.8,TAF13LGGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG7.6094e-040.1490image
chr1:109063122-109064145:-LGGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER7.2018e-040.1497image
chr1:109063122-109064145:-LIHCGSVA_HALLMARK_PEROXISOMEEER2.2706e-070.2770image
ENSG00000197780.8,TAF13LIHCGSVA_HALLMARK_PEROXISOMEEAG2.2754e-070.2770image
chr1:109063122-109064145:-LUADGSVA_HALLMARK_MYC_TARGETS_V1EER9.1528e-090.2551image
ENSG00000197780.8,TAF13LUADGSVA_HALLMARK_MYC_TARGETS_V1EAG5.7367e-090.2582image
ENSG00000197780.8,TAF13LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2855e-060.2140image
chr1:109063122-109064145:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5213e-060.2131image
ENSG00000197780.8,TAF13MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.4530e-02-0.2382image
chr1:109063122-109064145:-MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.4530e-02-0.2382image
ENSG00000197780.8,TAF13OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2291e-080.3238image
chr1:109063122-109064145:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6250e-080.3167image
chr1:109063122-109064145:-PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.2889e-030.2019image
ENSG00000197780.8,TAF13PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.2889e-030.2019image
chr1:109063122-109064145:-PCPGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.2488e-020.1888image
ENSG00000197780.8,TAF13PCPGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.3699e-020.1872image
ENSG00000197780.8,TAF13PRADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.1195e-02-0.1086image
chr1:109063122-109064145:-PRADGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.1245e-02-0.1086image
ENSG00000197780.8,TAF13SARCGSVA_HALLMARK_COMPLEMENTEAG1.4533e-020.1603image
chr1:109063122-109064145:-SARCGSVA_HALLMARK_COMPLEMENTEER1.4545e-020.1602image
chr1:109063122-109064145:-SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.2193e-06-0.2297image
ENSG00000197780.8,TAF13SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.3244e-06-0.2289image
ENSG00000197780.8,TAF13STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.1985e-03-0.1752image
chr1:109063122-109064145:-STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.2391e-03-0.1747image
ENSG00000197780.8,TAF13TGCTGSVA_HALLMARK_GLYCOLYSISEAG3.5998e-07-0.4051image
chr1:109063122-109064145:-TGCTGSVA_HALLMARK_GLYCOLYSISEER3.5998e-07-0.4051image
ENSG00000197780.8,TAF13THCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.4099e-04-0.1564image
chr1:109063122-109064145:-THCAGSVA_HALLMARK_PROTEIN_SECRETIONEER6.9400e-04-0.1572image
chr1:109063122-109064145:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER9.5173e-04-0.3354image
ENSG00000197780.8,TAF13THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.5173e-04-0.3354image
chr1:109063122-109064145:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0395e-030.2601image
ENSG00000197780.8,TAF13UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2529e-040.2904image
ENSG00000197780.8,TAF13UCSGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.8882e-020.3129image
chr1:109063122-109064145:-UCSGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.8882e-020.3129image
ENSG00000197780.8,TAF13UVMGSVA_HALLMARK_E2F_TARGETSEAG1.9995e-020.3973image
chr1:109063122-109064145:-UVMGSVA_HALLMARK_E2F_TARGETSEER1.9995e-020.3973image


Top

7. Enriched editing regions and drugs for TAF13


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:109063122-109064145:-ACCAS601245EER2.5546e-020.2906image
ENSG00000197780.8,TAF13ACCAS601245EAG2.5546e-020.2906image
chr1:109063122-109064145:-BLCAImatinibEER1.8547e-060.2493image
ENSG00000197780.8,TAF13BLCAImatinibEAG1.8816e-060.2491image
chr1:109063122-109064145:-BRCACMKEER9.9697e-05-0.1199image
ENSG00000197780.8,TAF13BRCACMKEAG4.9520e-05-0.1250image
chr1:109063122-109064145:-CESCBMS.536924EER1.1370e-10-0.3675image
ENSG00000197780.8,TAF13CESCBMS.536924EAG1.1370e-10-0.3675image
chr1:109063122-109064145:-CHOLMetforminEER9.3845e-04-0.5346image
ENSG00000197780.8,TAF13CHOLMetforminEAG9.3845e-04-0.5346image
chr1:109063122-109064145:-COADAZ628EER1.1539e-040.2582image
ENSG00000197780.8,TAF13COADAZ628EAG1.3179e-080.3715image
chr1:109063122-109064145:-DLBCDMOGEER1.2090e-030.5117image
ENSG00000197780.8,TAF13DLBCDMOGEAG1.2090e-030.5117image
chr1:109063122-109064145:-ESCAABT.888EER4.6107e-03-0.2250image
ENSG00000197780.8,TAF13ESCAABT.888EAG4.7396e-03-0.2236image
ENSG00000197780.8,TAF13GBMBMS.754807EAG7.1530e-060.3425image
chr1:109063122-109064145:-GBMBMS.754807EER7.2258e-060.3423image
chr1:109063122-109064145:-HNSCFH535EER5.8130e-050.1811image
ENSG00000197780.8,TAF13HNSCFH535EAG5.8130e-050.1811image
ENSG00000197780.8,TAF13KIRCBicalutamideEAG4.0851e-050.2153image
chr1:109063122-109064145:-KIRCBicalutamideEER4.1016e-050.2153image
chr1:109063122-109064145:-KIRPAUY922EER1.2260e-030.2096image
ENSG00000197780.8,TAF13KIRPAUY922EAG9.8807e-040.2135image
ENSG00000197780.8,TAF13LAMLImatinibEAG1.0664e-03-0.6625image
ENSG00000197780.8,TAF13LGGCMKEAG7.3178e-05-0.1752image
chr1:109063122-109064145:-LGGCMKEER6.8887e-05-0.1758image
chr1:109063122-109064145:-LIHCLFM.A13EER2.2301e-090.3180image
ENSG00000197780.8,TAF13LIHCLFM.A13EAG2.2368e-090.3180image
ENSG00000197780.8,TAF13LUADJW.7.52.1EAG6.0517e-04-0.1538image
chr1:109063122-109064145:-LUADGemcitabineEER7.3100e-04-0.1516image
chr1:109063122-109064145:-LUSCAP.24534EER3.8684e-050.1869image
ENSG00000197780.8,TAF13LUSCAP.24534EAG3.3078e-050.1885image
chr1:109063122-109064145:-MESOAS601245EER7.1968e-030.3002image
ENSG00000197780.8,TAF13MESOAS601245EAG7.1968e-030.3002image
ENSG00000197780.8,TAF13OVEmbelinEAG6.3306e-050.2347image
chr1:109063122-109064145:-OVEmbelinEER4.9073e-050.2381image
ENSG00000197780.8,TAF13PAADLenalidomideEAG3.9800e-02-0.1579image
chr1:109063122-109064145:-PAADLenalidomideEER3.9800e-02-0.1579image
chr1:109063122-109064145:-PCPGA.770041EER8.8605e-03-0.2166image
ENSG00000197780.8,TAF13PCPGA.770041EAG8.7295e-03-0.2171image
chr1:109063122-109064145:-PRADKIN001.135EER2.6689e-030.1413image
ENSG00000197780.8,TAF13PRADKIN001.135EAG2.7308e-030.1409image
ENSG00000197780.8,TAF13READFH535EAG2.6129e-020.2603image
chr1:109063122-109064145:-READFH535EER2.6129e-020.2603image
ENSG00000197780.8,TAF13SARCCisplatinEAG1.6161e-03-0.2059image
chr1:109063122-109064145:-SARCCisplatinEER1.4412e-03-0.2080image
chr1:109063122-109064145:-SKCMGNF.2EER1.3272e-06-0.2289image
ENSG00000197780.8,TAF13SKCMGNF.2EAG1.3530e-06-0.2287image
ENSG00000197780.8,TAF13STADABT.263EAG1.4589e-030.1725image
chr1:109063122-109064145:-STADABT.263EER1.2431e-030.1749image
ENSG00000197780.8,TAF13TGCTIPA.3EAG2.4376e-07-0.4104image
chr1:109063122-109064145:-TGCTIPA.3EER2.4376e-07-0.4104image
chr1:109063122-109064145:-THCALapatinibEER1.7723e-030.1451image
ENSG00000197780.8,TAF13THCALapatinibEAG1.7351e-030.1453image
chr1:109063122-109064145:-THYMBAY.61.3606EER1.5335e-040.3807image
ENSG00000197780.8,TAF13THYMBAY.61.3606EAG1.5335e-040.3807image
chr1:109063122-109064145:-UCECGefitinibEER4.9522e-04-0.2757image
ENSG00000197780.8,TAF13UCECGefitinibEAG5.1981e-04-0.2738image
ENSG00000197780.8,TAF13UCSCI.1040EAG3.2066e-03-0.3871image
chr1:109063122-109064145:-UCSCI.1040EER3.2066e-03-0.3871image
ENSG00000197780.8,TAF13UVMDMOGEAG1.6061e-030.5204image
chr1:109063122-109064145:-UVMDMOGEER1.6061e-030.5204image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType